• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016-2017 winter season in Israel

tetano

Editor, Senior Moderator
J Clin Virol. 2017 Jun 4;93:71-75. doi: 10.1016/j.jcv.2017.05.020. [Epub ahead of print]
[h=1]Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016-2017 winter season in Israel.[/h] Glatman-Freedman A[SUP]1[/SUP], Drori Y[SUP]2[/SUP], Beni SA[SUP]3[/SUP], Friedman N[SUP]2[/SUP], Pando R[SUP]4[/SUP], Sefty H[SUP]5[/SUP], Tal I[SUP]3[/SUP], McCauley J[SUP]6[/SUP], Rahav G[SUP]7[/SUP], Keller N[SUP]8[/SUP], Shohat T[SUP]9[/SUP], Mendelson E[SUP]2[/SUP], Hindiyeh M[SUP]2[/SUP], Mandelboim M[SUP]10[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] Influenza vaccine composition is reevaluated each year due to the frequency and accumulation of genetic changes that influenza viruses undergo. The beginning of the 2016-2017 influenza surveillance period in Israel has been marked by the dominance of influenza A(H3N2).
[h=4]OBJECTIVES:[/h] To evaluate the type, subtype, genetic evolution and amino acid substitutions of influenza A(H3N2) viruses detected among community patients with influenza-like illness (ILI) and hospitalized patients with respiratory illness in the first weeks of the 2016-2017 influenza season.
[h=4]STUDY DESIGN:[/h] Respiratory samples from community patients with influenza-like illness and from hospitalized patients underwent identification, subtyping and molecular characterization. Hemagglutinin sequences were compared to the vaccine strain, phylogenetic tree was created, and amino acid substitutions were determined.
[h=4]RESULTS:[/h] Influenza A(H3N2) predominated during the early stages of the 2016-2017 influenza season. Noticeably, approximately 20% of community patients and 36% of hospitalized patients, positive for influenza[SUB]3[/SUB]), received the 2016-2017 influenza vaccine. The influenza A(H3N2) viruses demonstrated genetic divergence from the vaccine strain into three separate subgroups within the 3C.2a clade. One resembled the new 3C.2a1 subclade, one resembled the recently proposed 3C.2a2 subclade and the other was not previously described. Diversity was observed within each subgroup, in terms of additional amino acid substitutions.
[h=4]CONCLUSIONS:[/h] Characterization of the 2016-2017 A(H3N2) influenza viruses is imperative for determining the future influenza vaccine composition.
Copyright ? 2017. Published by Elsevier B.V.


[h=4]KEYWORDS:[/h] Clade 3C.2a1; H(3)N(2); Influenza A; Influenza vaccine

PMID: 28672275 DOI: 10.1016/j.jcv.2017.05.020
 
Back
Top Bottom